Blog

Blog

Welcometo Antibody Basics by Biointron,Part 8. In this episode, we’ll talk about therapeutics targeting cancer.What is cancer immunotherapy?Cancer immunotherapy leverages the body's immune system to fight cancer more selectively and effectively than traditional methods such as chemotherapy

May 24, 2024
Read time: 10 mins

The generation of an immune response to a vaccine. DOI: 10.1038/s41577-020-00479-7Vaccination is one of the most effective tools in preventing infectious diseases. At its core, the success of a vaccine hinges on its ability to induce a robust and lasting antibody response against a specific pathogen

May 22, 2024
Read time: 3 mins

Innovation orientation and goals for transforming CAR-T cell engineering. DOI: 10.1186/s13045-020-00910-5Chimeric antigen receptor (CAR)-T cell therapy is a revolutionary cancer treatment in which engineered CARs redirect lymphocytes, typically T cells, to recognize and destroy cells expressing a sp

May 20, 2024
Read time: 3 mins

The 20th Annual PEGS Boston Summit 2024 was held in Boston, MA from May 13-17. During the event, industry experts from across the world gathered to share the latest research in advancements in drug development, protein and antibody engineering, immunotherapy, immunogenicity, expression platforms, mu

May 18, 2024
Read time: 4 mins

Image credit: Johnson & Johnson Archives Muronomab-CD3, also known by its trade name Orthoclone OKT3, is historically significant as it was the first monoclonal antibody approved by the U.S. Food and Drug Administration (FDA) for use in humans in 1986, for the pr

May 16, 2024
Read time: 4 mins

The differences of scFv and nanobody in structure.DOI:10.1186/s40364-021-00332-6Antibody engineering has significantly advanced with the development of various formats that enhance therapeutic efficacy and diagnostic precision. Single-chain variable fragments (scFvs) represent one of t

May 14, 2024
Read time: 4 mins

The Chinese Antibody Society (CAS) Annual Conference 2024 was held in Boston, MA on May 11. The meeting was titled “Beyond Borders: Advancements in Antibody-Based Therapeutics in Uncharted Territories” and featured the latest advancements in therapeutic antibodies, in addition to

May 12, 2024
Read time: 3 mins

Biointron’s Lunch & Learn with MassBio was held in Boston, MA on May 9. The session focused on the advancements in next-generation HTP antibody and antibody-drug conjugate (ADC) development in the biopharma industry and featured two key speakers: Biointron’s SVP of R&D, Dr. Lei Shi, and ImmuVia’s CSO, Dr. Victor Goldmacher. We thoroughly enjoyed hosting the event and the audience’s strong engagement!

May 10, 2024
Read time: 4 mins

Modified versions of antibodies have been designed to improve certain properties or functionalities, e.g. to enhance their therapeutic or diagnostic potential.

May 08, 2024
Read time: 2 mins

VHH antibodies, also known as single-domain antibodies (sdAbs) or nanobodies, are a class of antibodies found in camels, llamas, alpacas, and other camelids. These unique molecules have revolutionized the field of antibody research due to their unique properties and potential applications for therapeutics.

May 04, 2024
Read time: 4 mins

Bispecific antibody-drug conjugates (bsADCs) are an emerging class of therapeutics that combine the dual-targeting capabilities of bispecific antibodies (bsAbs) with the potent cytotoxic action of antibody-drug conjugates (ADCs). This innovative, next-generation ADC approach aims to enhance the selectivity and efficacy of cancer treatments, offering new hope in the fight against complex malignancies. As of January 2024, there are 10 bsADCs in clinical trials, but none are approved fully yet.

May 02, 2024
Read time: 5 mins

Transgenic animals are organisms genetically modified to contain one or more foreign genes, known as transgenes, inserted into their genome. These transgenes can be introduced using various genetic engineering techniques, with the goal of conferring specific traits or characteristics onto the animal. In the context of antibody discovery and therapeutic development, transgenic animals can be engineered to express human antibody genes, enabling them to produce fully human antibodies for research and therapeutic purposes.

Apr 30, 2024
Read time: 5 mins

keep yourself updated with Biointron Insights

Our website uses cookies to improve your experience. Read our Privacy Policy to find out more.